Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                  July 6, 2006
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

          DELAWARE                 000-29089                    06-1562417
(State or other jurisdiction      (Commission                 (IRS Employer
       of incorporation)          File Number)             Identification No.)

                   630 Fifth Avenue, Suite 2100
                        New York, NY 10111                           10111
             (Address of principal executive offices)             (Zip Code)

              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

Item 1.01         Entry into a Material Definitive Agreement

                  On July 6, 2006, Antigenics Inc. entered into expanded license
and supply agreements for the use of QS-21 Stimulon(R) adjuvant with
GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). Under
the terms of the agreements, GSK will purchase a percentage of its QS-21 supply
requirements from Antigenics through 2014. Antigenics will also transfer
manufacturing technologies to GSK under the supply agreement. GSK will make
payments contingent upon successful milestone achievements, and will pay
royalties to Antigenics on net sales for a period of at least 10 years after
first commercial sale under the supply agreement.

Item 7.01         Regulation FD Disclosure

                  On July 10, 2006, Antigenics Inc. issued a press release
announcing the execution of the agreements described in Item 1.01 above. The
full text of the press release issued in connection with the announcement is
being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01         Financial Statements and Exhibits

         (d) Exhibits

         The following exhibit is furnished herewith:

                           99.1     Press Release dated July 10, 2006


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                                ANTIGENICS INC.

Date:    July 10, 2006
                                           By:         /s/ Garo H. Armen, Ph.D.
                                                           Garo H. Armen, Ph.D.
                                           Chairman and Chief Executive Officer


Exhibit No.       Description of Exhibit
-----------       ----------------------

99.1              Press Release dated July 10, 2006